Cargando…

Human regular U‐500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study

AIM: To compare the safety and efficacy of U500‐R delivered by a novel, specifically designed U500‐R insulin pump with U‐500R delivered by multiple daily injections (MDI). METHODS: The phase 3 VIVID study randomized people with type 2 diabetes to U‐500R by continuous subcutaneous insulin infusion (C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grunberger, George, Bhargava, Anuj, Ly, Trang, Zisser, Howard, Ilag, Liza L., Malone, James, Fan, Ludi, Zhang, Shuyu, Johnson, Jennal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065168/ https://www.ncbi.nlm.nih.gov/pubmed/31865633 http://dx.doi.org/10.1111/dom.13947

Ejemplares similares

Patient‐reported outcomes in a study of human regular U‐500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetes
por: Chen, Jieling, et al.
Publicado: (2020)

Delayed Response to U-500 Regular Insulin
por: Davidson, Mayer B.
Publicado: (2018)

Insulin Edema With Use of U-500 Regular Insulin in a Hybrid Closed-Loop Insulin Pump
por: Vasigh, Mostafa, et al.
Publicado: (2020)

Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?
por: Rosinha, Patrícia, et al.
Publicado: (2022)

MON-152 Less Is More: Human Regular U-500 Insulin
por: Lugo Lopez, Zahira, et al.
Publicado: (2019)

Continuous subcutaneous insulin infusion: practical issues
por: Saboo, Banshi D., et al.
Publicado: (2012)

Comparison of Glycemic Control between Continuous Regular Insulin Infusion and Single-dose Subcutaneous Insulin Glargine Injection in Medical Critically Ill Patients
por: Bhurayanontachai, Rungsun, et al.
Publicado: (2018)

Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus
por: Pettitt, D. J., et al.
Publicado: (2007)

Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear
por: Rini, Christopher James, et al.
Publicado: (2015)

FRI654 Concentrated Regular U-500 Insulin In An Automated Insulin Delivery System: A Case Report
por: Aurora, John, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects
por: de la Peña, Amparo, et al.
Publicado: (2011)

Continuous subcutaneous insulin infusion therapy is associated with reduced retinopathy progression compared with multiple daily injections of insulin
por: Reid, Laura J., et al.
Publicado: (2021)

A Continuous Subcutaneous Insulin Infusion Needle Break
por: George, Minu M., et al.
Publicado: (2015)

U-500 Regular Insulin: Clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients
por: Davidson, Mayer B., et al.
Publicado: (2010)

Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes
por: Kapitza, Christoph, et al.
Publicado: (2010)

Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes
por: GAO, GUAN-QI, et al.
Publicado: (2014)

Psychopathology and Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes
por: Rotella, Francesco, et al.
Publicado: (2013)

Duration and onset of action of high dose U‐500 regular insulin in severely insulin resistant subjects with type 2 diabetes
por: Shrestha, Rupendra T., et al.
Publicado: (2018)

Carbohydrate Requirements for Prolonged, Fasted Exercise With and Without Basal Rate Reductions in Adults With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion
por: McGaugh, Sarah M., et al.
Publicado: (2021)

Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
por: Lim, Beng Leong, et al.
Publicado: (2023)

Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
por: Li, Feng-fei, et al.
Publicado: (2018)

Effect of the Concomitant Use of Subcutaneous Basal Insulin and Intravenous Insulin Infusion in the Treatment of Severe Hyperglycemic Patients
por: Lim, Yejee, et al.
Publicado: (2022)

Evaluation of the Accuracy of Current Tubeless Pumps for Continuous Subcutaneous Insulin Infusion
por: Ziegler, Ralph, et al.
Publicado: (2021)

Development and Implementation of a U-500 Regular Insulin Program in a Federally Qualified Health Center
por: Shaw, Kathy F., et al.
Publicado: (2017)

The OmniPod Insulin Management System: the latest innovation in insulin pump therapy
por: Zisser, Howard C.
Publicado: (2010)

Insulin Pump for Type 2 Diabetes: Use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes
por: Reznik, Yves, et al.
Publicado: (2013)

Detailed Analysis of Insulin Absorption Variability and the Tissue Response to Continuous Subcutaneous Insulin Infusion Catheter Implantation in Swine
por: Hauzenberger, Jasmin R., et al.
Publicado: (2017)

A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
por: King, Allen B., et al.
Publicado: (2016)

Continuous subcutaneous insulin infusion is associated with a reduced rate of microvascular complications
por: Zabeen, Bedowra, et al.
Publicado: (2015)

Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics
por: Pozzilli, Paolo, et al.
Publicado: (2015)

Continuous subcutaneous insulin infusion and flash glucose monitoring in diabetic hemiballism-hemichorea
por: Qiang, Wei, et al.
Publicado: (2020)

Changes in Basal Insulin Infusion Rates With Subcutaneous Insulin Infusion: Time until a change in metabolic effect is induced in patients with type 1 diabetes
por: Heinemann, Lutz, et al.
Publicado: (2009)

Lilly Insulin Glargine Versus Lantus(®) in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)
por: Pollom, Robyn K., et al.
Publicado: (2019)

Diurnal variation of carbohydrate insulin ratio in adult type 1 diabetic patients treated with continuous subcutaneous insulin infusion
por: Nakamura, Tomoaki, et al.
Publicado: (2014)

Advancing Patient Safety and Access to Concentrated Insulin (U-500 Regular Insulin) in the Veterans Health Administration: A Clinician Education Program in the Primary Care Setting
por: Lutz-McCain, Stacey J., et al.
Publicado: (2018)

Changes in Glycemic Control and Quality of Life in Pediatric Type 1 Diabetics with Continuous Subcutaneous Insulin Infusion of Insulin Aspart Following Multiple Daily Injection Therapy
por: Kawamura, Tomoyuki, et al.
Publicado: (2008)

Human Regular 500 units/mL Insulin Therapy: A Review of Clinical Evidence and New Delivery Options
por: Sze, David, et al.
Publicado: (2018)

Continuous Subcutaneous Insulin Infusion Characteristics in Type 1 Diabetes Children and Adolescents in Qatar
por: Petrovski, Goran, et al.
Publicado: (2018)

Effectiveness of Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion for Children with Type 1 Diabetes Mellitus in Clinical Practice
por: Gong, Chun-xiu, et al.
Publicado: (2014)

Study protocol for a randomised controlled trial of insulin delivery by continuous subcutaneous infusion compared to multiple daily injections
por: Blair, Jo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1elm6uvshbmrmrk2d6foblkmfe